Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.

被引：0
|
作者：
Warner, Allison Betof [1 ]
Shoushtari, Alexander Noor [1 ]
Houghton, Sean [1 ]
Panageas, Katherine [1 ]
Chapman, Paul B. [1 ]
Wolchok, Jedd D. [1 ]
Postow, Michael A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9552
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.
    Larkin, James
    Gogas, Helen
    Del Vecchio, Michele
    Maio, Michele
    Arenberger, Petr
    Arance, Ana Maria
    Grob, Jean-Jacques
    Chiarion-Sileni, Vanna
    Lewis, Karl D.
    Mortier, Laurent
    Ott, Patrick Alexander
    Long, Georgina V.
    Van Den Eertwegh, Alfonsus
    Cowey, C. Lance
    Schenker, Michael
    Butler, Marcus O.
    Lobo, Maurice
    Askelson, Margarita
    Ascierto, Paolo Antonio
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
    Callahan, Margaret K.
    Kania, Brooke Elizabeth
    Iyer, Gopa
    Clement, Jessica Mary
    Funt, Samuel
    McCoy, Asia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [43] Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
    Johnson, Jennifer Maria
    Bar Ad, Voichita
    Lorber, Emily
    Poller, Dawn
    Manukian, Gregor
    Luginbuhl, Adam
    Curry, Joseph M.
    Cognetti, David M.
    Keith, Scott W.
    Axelrod, Rita Susan
    Rodeck, Ulrich
    Harshyne, Larry
    Argiris, Athanassios
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
    El-Khoueiry, Anthony B.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Lim, Ho Yeong
    Memaj, Arteid
    Sama, Ashwin Reddy
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [45] CLINICAL RESPONSE, PROGRESSION-FREE SURVIVAL (PFS) AND SAFETY IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) RECEIVING NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI MONOTHERAPY IN CHECKMATE 069 STUDY
    Hodi, F. Stephen
    Postow, Michael A.
    Chesney, Jason
    Pavlik, Anna C.
    Robert, Caroline
    Grossman, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey K.
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David
    Salama, April K.
    Taylor, Matthew
    Ott, Patrick A.
    Horak, Christine
    Gagnier, Paul
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 109 - 109
  • [46] Nivolumab (NIVO) plus /- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naive or -refractory basal cell carcinoma (BCC)
    Schenk, K. M.
    Deutsch, J. S.
    Schollenberger, M. D.
    Sharfman, W. H.
    Brothers, P. N.
    Pons, A.
    Scott, J. F.
    Bibee, K.
    Taube, J. M.
    Topalian, S. L.
    Lipson, E. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S922 - S923
  • [47] Toxicity associated with ipilimumab and nivolumab (Ipi plus Nivo) combination therapy in melanoma patients (pts) treated at a single-institution under an expanded-access program (EAP).
    Friedman, Claire Frances
    Navid-Azarbaijani, Pedram
    Shoushtari, Alexander Noor
    Campbell, Shonnette C.
    Callahan, Margaret K.
    Momtaz, Parisa
    Prempeh-Keteku, Nana A.
    Postow, Michael Andrew
    Shames, Yelena
    Wolchok, Jedd D.
    Chapman, Paul B.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [48] PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis
    Long, G. V.
    Larkin, J.
    Ascierto, P. A.
    Hodi, F. S.
    Rutkowski, P.
    Sileni, V.
    Hassel, J.
    Lebbe, C.
    Pavlick, A. C.
    Wagstaff, J.
    Schadendorf, D.
    Dummer, R.
    Hogg, D.
    Haanen, J. B. A. G.
    Corrie, P.
    Hoeller, C.
    Horak, C.
    Wolchok, J.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma.
    Gaughan, Elizabeth Mary
    Petroni, Gina R.
    Grosh, William W.
    Slingluff, Craig L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] TWO-YEAR OVERALL SURVIVAL (OS) RATES FROM A RANDOMIZED PHASE 2 TRIAL EVALUATING THE COMBINATION OF NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) VERSUS IPI IN PATIENTS WITH ADVANCED MELANOMA (MEL)
    Postow, Michael A.
    Chesney, Jason
    Pavlick, Anna C.
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Linette, Gerald
    Meyer, Nicolas
    Giguere, Jeffrey
    Agarwala, Sanjiv S.
    Shaheen, Montaser
    Ernstoff, Marc S.
    Minor, David R.
    Salama, April
    Taylor, Matthew H.
    Ott, Patrick A.
    Jiang, Joel
    Horak, Christine
    Wolchok, Jedd D.
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 130 - 131
12345